ibipinabant
Ibipinabant (SLV319, BMS-646,256) was designed by Jos Lange at Solvay Pharmaceuticals in 2000. Nowadays, it is an in vivo active pharmacological tool used in scientific research which acts as a potent and highly selective CB1 antagonist. It has potent anorectic effects in animals, and was researched for the treatment of obesity, although CB1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagonists. SLV330, which is a structural analogue of Ibipinabant, was reported active in animal models related to the regulation of memory, cognition, as well as in addictive behavior. An atom-efficient synthesis of ibipinabant has been reported. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Nov 1, 2006 (NCT00388609)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cannabinoid CB1 receptorANTAGONIST
CNR1 antagonist
Ph 2 study terminated and Ph2/3 study withdrawn, development Discontinuedbecause of potential serious side effects linked to targetting of CNR1 (http://en.wikipedia.org/wiki/Ibipinabant).
Chemistry & pharmacology
SMILES
CN/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1C[C@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1- Mol. weight
- 487.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIbipinabant ↗
- ChEMBLCHEMBL412262 ↗
Also known as
- 3-(4-chlorophenyl)-n-((4-chlorophenyl)sulfonyl)-4,5-dihydro-n'-methyl-4-phenyl-1h-pyrazole-1-carboximidamide
- 3-(4-chlorophenyl)-n-methyl-n'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamidine
- bms-646256
- bms-646256
- bms-646256
- ibipinabant
- ibipinabant
- ibipinabant
- ibipinabant
- ibipinabant
- slv319
- slv 319
- slv-319
- slv-319
- slv-319
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00541567 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2008 | Bristol-Myers Squibb, Solvay |
| NCT00388609 | Phase 2 | Nov 1, 2006 | Bristol-Myers Squibb, Solvay |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 1 | 2 | 2006 |
| Solvay | For profit | 2 | 1 | 2 | 2006 |